Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial).

Marie L JohansenMorten SchouPatrick RossignolMaria R HolmJon RasmussenNiels BrandtMikkel FrandsenElizaveta ChabanovaFlemming DelaJens FaberCaroline Kistorp

Published in: Diabetes, obesity & metabolism (2019)

The addition of high doses of eplerenone to background antidiabetic and antihypertensive therapy does not show beneficial effects on liver fat and metabolism in patients with T2D.

Keyphrases

double blind
study protocol
phase iii
adipose tissue
clinical trial
phase ii
placebo controlled
blood pressure
fatty acid
randomized controlled trial
open label
stem cells
hypertensive patients
cell therapy
bone marrow